Brain Injury Biomarkers in the General Population
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
California
-
Vista, California, United States, 92083
- Office of Nagi S. Ibrahim
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Shands at University Florida Gainesville
-
-
Georgia
-
Decatur, Georgia, United States, 30033
- Dekalb Medical Center
-
Lawrenceville, Georgia, United States, 30045
- Gwinnett Medical Center
-
-
Massachusetts
-
Fall River, Massachusetts, United States, 02720
- New England Center for Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- At least 18 years of age and no more than 80 years of age
- Willing to undergo consent
- PI believes volunteer is appropriate candidate for study
Exclusion Criteria:
- Participating in another clinical study that may affect the results of either study
- Non-English speaking
- Venipuncture not feasible
- Blood donation within 1 week of screening
- PI determines volunteer is not medically suitable for study participation
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Healthy Volunteers
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Assessment of the putative biomarkers for TBI markers in general population using an investigational assay
Time Frame: up to 21 days
|
up to 21 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Correlation of the putative biomarkers for TBI levels in general population to levels in patients with severe TBI
Time Frame: 0, 14, 7, and 21 days
|
0, 14, 7, and 21 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ATO-05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.